Clinical Trial

US Zamto-cel Autoimmune Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-26.
Status change: Not Yet Recruiting → Recruiting 2026-06-09
Trial Details
NCT Number NCT06708845
Lead Sponsor Miltenyi Biomedicine GmbH
Conditions Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
Enrollment 48 participants
Start Date 2026-07
Primary Completion 2028-01 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-11